STAT3 and gastric cancer: As demonstrated by Ma et al., JAK/STAT3-activating IL-11 promotes acquired chemoresistance in GC, followed by a cascading effect that consequently induces anti-apoptosis and diminishes therapeutic outcome (Ma et al., 2019a).